caa a22 4500 475818253 CHVBK 20180406123815.0 cr unu---uuuuu 170329e20000401xx s 000 0 eng 10.1007/s002280050728 doi (NATIONALLICENCE)springer-10.1007/s002280050728 Workplace drug testing (WDT) likely to increase in Europe [Elektronische Daten] Report from the First European Symposium on WDT including selected abstracts [P. Dalén, O. Beck, U. Bergman, P. Björklöv, D. Finer, M. Garle, F. Sjöqvist] Will it take a series of drug-related accidents that have already occurred in the USA before workplace drug testing (WDT) becomes accepted in Europe as a preventive measure? Currently, the development of WDT in most European countries lags some 10-15 years behind that in the USA. - Labour authorities in Europe now ought to take initiatives to demand a mandatory programme for accrediting drug analytical laboratories for WDT. - Companies should realise that illicit drug use is no longer only a problem at street corners, and that having a testing system in place is important, not just for public health, but also for their reputations as responsible societal actors. - Improved networking among police and regulatory authorities is required to keep pace with the rapid appearance and dissemination of new substances of abuse. - European research collaboration, including the newly formed European Workplace Drug Testing Group, is needed to assess the impact of drug-testing policies on accidents and other outcome variables, and thereby to convince the general public and politicians that drug testing is beneficial and necessary. - A 1993-1994 survey of quality analysis in some 200 European laboratories reported from Institut Municipal d'Investigació Mèdica (IMIM), Spain, showed good agreement between nominal and found concentrations but that only 10% of the laboratories could both screen, identify and quantify samples. - Experiences from Italy show that proficiency testing schemes lead to improved accuracy of results. These were some major conclusions of the First European Symposium on Drug Testing held at Huddinge University Hospital in Stockholm, Sweden, 30 March to 1 April 1998, organised by Karolinska Institute, with participants from 22 countries. Springer-Verlag Berlin Heidelberg, 2000 Dalén P. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Beck O. Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden, SE aut Bergman U. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Björklöv P. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Finer D. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Garle M. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Sjöqvist F. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut https://doi.org/10.1007/s002280050728 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050728 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dalén P. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut NATIONALLICENCE 700 1- Beck O. Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden, SE aut NATIONALLICENCE 700 1- Bergman U. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut NATIONALLICENCE 700 1- Björklöv P. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut NATIONALLICENCE 700 1- Finer D. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut NATIONALLICENCE 700 1- Garle M. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut NATIONALLICENCE 700 1- Sjöqvist F. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden e-mail: Ulf.Bergman@pharmlab.hs.sll.se, SE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer